Test Price
2,800 AED✅ Home Collection Available
KRAS Gene Noonan Syndrome Type 3 Genetic Test in UAE | 2800 AED | DHA Licensed
Executive Summary & Core Metrics
Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO 9001:2015 Certified Processing (Cert: INT/EGQ/2509DA/3139).
Premium Logistics: VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection – available daily from 8 AM to 11 PM.
Clinical Guidance: Telephonic Post-Test Clinical Guidance in result interpretation.
Insurance: Direct Billing Verification via WhatsApp +971 54 548 8731 (use support number +971545488731).
Test Overview & Methodology
This advanced Next-Generation Sequencing (NGS) analysis detects pathogenic variants in the KRAS gene associated with Noonan syndrome type 3 and related RASopathies. The test delivers definitive molecular confirmation for dysmorphology evaluation, guiding personalised care and genetic counselling.
| Feature | Our Test (NGS‑based) | Closest Alternative (Sanger) |
|---|---|---|
| Precision | Full coding region +‑10 bp intronic flanks | Single‑exon resolution, limited to known hot‑spots |
| Methodology | Illumina NGS, ACMG‑compliant bioinformatics | Capillary sequencing (Sanger) |
| Turnaround Time | 3–4 Weeks | 4–6 Weeks |
| Clinical Report | Includes variant classification & literature references | Basic absent/present result |
Physician Insight & Safety Protocols
“As a consultant medical geneticist, I understand the anxiety a suspected Noonan syndrome diagnosis brings. This NGS test provides precise molecular clarity, enabling early cardiac and developmental surveillance. However, a negative result does not exclude all RASopathies, and clinical correlation remains essential.” — Lina Osama Zaki Quteineh, DHA Registration ID: 9294403
Advisory on Medication & Result Interpretation
⚠ Medication Warning
Do not discontinue prescribed medication without consulting your doctor. Interpretation of KRAS results must be integrated with clinical findings; altering therapy based solely on this test may be harmful.
Exclusion Criteria & Emergency Red Flags
- Not suitable for individuals under age 18 without documented parental consent (UAE Personal Data Protection Law and Federal Law No. 2 of 2019).
- Patients with acute bleeding disorders or severe thrombocytopenia require a pre‑collection risk assessment.
- Test not intended for asymptomatic “wellness” screening without genetic counselling.
- Seek immediate medical attention if the patient develops chest pain, severe shortness of breath, or cyanosis – these may indicate a cardiac complication unrelated to the test but requiring urgent care.
Patient FAQ & Clinical Guidance
1. What is the KRAS gene Noonan syndrome type 3 test?
This test uses Next‑Generation Sequencing to detect pathogenic KRAS mutations linked to Noonan syndrome type 3. It analyses the entire coding region of the KRAS gene from a blood or DNA sample, providing a definitive molecular diagnosis when clinical features suggest a RASopathy. Results guide paediatric cardiology, growth, and developmental follow‑up.
2. How is the sample collected for this KRAS NGS?
A small blood sample (3–5 mL in EDTA) or dried blood spot card is collected through a standard venipuncture. Our home phlebotomy team performs the collection using cold‑chain transport; no fasting is required. For minors, a parent or legal guardian must be present and provide consent.
3. What does a positive test result mean for my child’s health?
A pathogenic mutation confirms the diagnosis and guides early cardiac and developmental monitoring per DHA guidelines. A positive result allows precise genetic counselling and assessment of recurrence risk in the family. A negative result does not completely rule out similar syndromes; clinical evaluation remains essential.
UAE Regulatory & Data Privacy Adherence
Data Protection & Privacy: All genetic data is processed in strict compliance with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Clinical safety and patient consent adhere to Federal Decree-Law No. 4 of 2016 on Medical Liability.
Accreditation: DHA Facility License No. 1143 | ISO 9001:2015 Certified (Cert: INT/EGQ/2509DA/3139).
Sample Processing: Illumina NGS platform with bioinformatic pipelines validated against DHA and ACMG/AMP variant interpretation standards.
Medical Enquiries & Support: +971545488731 (WhatsApp enabled for direct billing verification and appointment booking).
Clinical & Logistical Metadata
| Test Name | KRAS Gene Noonan Syndrome Type 3 Genetic Test (NGS) |
| Price (AED) | 2,800 AED |
| Turnaround Time | 3–4 Weeks |
| Sample Type / Matrix | Peripheral Blood (EDTA) or Dried Blood Spot |
| Methodology Used | Next-Generation Sequencing (Illumina NGS) |
| ICD-10-CM Code | Q87.1 |
| LOINC Code | 91699-4 |
| DHA Facility License & Address | License No. 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE – DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians